Risk of Herpes zoster in patients with psoriasis treated with biologic drugs

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 9, 2012, Pages 1127-1132

  Dreiher, J ^a,b   Kresch, F S ^a   Comaneshter, D ^a   Cohen, A D ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEALTH CARE UTILIZATION; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; ULTRAVIOLET B RADIATION;

BIOLOGICAL AGENTS; CASE-CONTROL STUDIES; HERPES ZOSTER; HUMANS; INCIDENCE; ISRAEL; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84865077600     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04230.x     Document Type: Article

References (28)

1. Ghasri P, Yamauchi PS,. The role of methotrexate in the era of biological therapies for treating psoriasis. Adv Psor Inflamm Skin Dis 2010; 2: 39-45.
2. Krueger JG,. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
3. Gómez-Reino JJ, Carmona L, Angel Descalzo M,. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.
4. Brassard P, Kezouh A, Suissa S,. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-722.
5. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-1133.
6. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO,. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265.
7. Whitley RJ,. Varicella-Zoster virus infections. In:, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 17th edn. McGraw-Hill, New York, 2008: 1102-1105.
8. Gnann JW Jr, Whitley RJ,. Clinical practice: herpes zoster. New Engl J Med 2002; 347: 340-346.
9. Straus SE, Oxman MN, Schmader KE,. Varicella and herpes zoster. In:, Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine, 7th Edn. McGraw-Hill, New York, 2008.
10. Whitley RJ, Gnann JW Jr,. Herpes zoster in the age of focused immunosuppressive therapy. JAMA 2009; 301: 774-776.
11. Thomas SL, Hall AJ,. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4: 26-33.
12. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57: 1431-1438.
13. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009; 301: 737-744.
14. Dreiher J, Weitzman D, Cohen AD,. Psoriasis and osteoporosis: a sex-specific association? J Invest Dermatol 2009; 129: 1643-1649.
15. Birkenfeld S, Dreiher J, Weitzman D, Cohen AD,. Coeliac disease associated with psoriasis. Br J Dermatol 2009; 161: 1331-1334.
16. Cohen AD, Weitzman D, Birkenfeld S, Dreiher J,. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010; 220: 218-222.
17. Winthrop KL, Furst DE,. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumor necrosis factor therapy. Ann Rheum Dis 2010; 69: 1735-1737.
18. Langley RGB, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005; 27: 1317-1328.
19. Antoniou C, Stefabaki I, Stratigos A, et al. The Greek experience with efalizumab in psoriasis from a university dermatologic hospital. Br J Dermatol 2007; 156: 12-16.
20. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-1371.
21. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412.
22. Wolfe F, Michaud K, Chakravarty EF,. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology 2006; 45: 1370-1375.
23. Wendling D, Streit G, Toussirot E, Prati C,. Herpes zoster in patients raking TNF-α antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75: 540-543.
24. Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-1490.
25. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-623.
26. Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rhuem Dis 2010; 69: 1751-1755.
27. Domm S, Cinatl J, Mroweitz U,. The impact of treatment with tumor necrosis factor-α anatagonists on the course of chronic viral infections: a review of the literature. Br J Derm 2008; 159: 1217-1228.
28. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rate of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349.